Peking University Cancer Hospital
北京大学肿瘤医院
elsewhere's corpus does not cover Peking University Cancer Hospital as a subject in its own right. The only mentions in the bundle are passing references in articles about the AI microbiome drug developer Unknown (未知君), which note clinical collaborations between Unknown and the hospital . These pieces, published by 5Y Capital and Gaorong Ventures in 2019 and 2021, do not provide any institutional profile, founding details, scale, or specializations of the hospital itself.
AI-generated — may contain errors, please verify.
Coverage
Unknown Closes Nearly $100 Million in Series B Funding, Launches AI×BT Strategy
Focused on gut microbiome AI-driven drug discovery, with self-developed drug candidates already in registrational clinical trials.
5Y News | AI Microbiome Drug Developer "Unknown" Closes Nearly $100 Million Series B Financing
Launching a new AI×BT strategy.
5Y News｜Unknown Closes Tens of Millions of Dollars in Series B+ Funding to Advance Microbiome Drug Clinical Trials
Leading domestic microbiome therapeutics company Unknown has recently completed a tens-of-millions-of-dollars Series B+ funding round, with continued backing from 5Y Capital.
China's First AI Microbiome Drug Company "Unknown" Raises Nearly $10 Million in Funding
Leveraging AI and bioengineering technologies to deliver precision management of gut health for Chinese consumers.
